Business Standard

Coronavirus Vaccine Shows Promising Early Results in China

The early-stage trial, published in the Lancet, was conducted by researchers at several laboratories and included 108 participants aged 18 to 60

testing, private laboratories, labs, vaccines, doctors, nurses, health, coronavirus
Premium

The researchers in China did find that people who had Ad5 antibodies were less likely to develop a strong immune response to the vaccine

Apoorva Mandavilli | NYT
A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.

The early-stage trial, published in the Lancet, was conducted by researchers at several laboratories and included 108 participants aged 18 to 60. Those who received a single dose of the vaccine produced certain immune cells, called T cells, within two weeks. Antibodies needed for immunity peaked at 28 days after the inoculation.

“This is promising data, but it’s early data,” said Dr. Dan Barouch, director of vaccine research at Beth Israel Deaconess Medical Center in Boston, who was not involved in

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 24 2020 | 12:16 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com